Trial Profile
A Randomized, Double Blind, Placebo Controlled, Phase III Study of KUC-7483 in Patients With Overactive Bladder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Aug 2010
Price :
$35
*
At a glance
- Drugs Ritobegron (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 26 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jul 2010 Interim results released in a Kissei Pharmaceuticals media release. The company intends to perform a detailed analysis prior to making a decision regarding further development of KUC 7483.
- 02 Jul 2010 Primary endpoint 'Micturition rate' has not been met.